These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

836 related items for PubMed ID: 30572906

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cutaneous Lupus Erythematosus Patients With a Negative Antinuclear Antibody Meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus.
    Tarazi M, Gaffney RG, Kushner CJ, Chakka S, Werth VP.
    Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1404-1409. PubMed ID: 31058462
    [Abstract] [Full Text] [Related]

  • 5. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, Danoff D, Osterland CK, Yeadon C, Smith CD.
    Lupus; 1998 Nov; 7(2):80-5. PubMed ID: 9541091
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS.
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up.
    Bortoluzzi A, Furini F, Campanaro F, Govoni M.
    Lupus; 2017 May; 26(6):616-622. PubMed ID: 27703051
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.
    James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, Walker C, Dennis GJ, Merrill JT, Harley JB.
    Lupus; 2007 May; 16(6):401-9. PubMed ID: 17664230
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.
    Urowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcón GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C.
    Arthritis Care Res (Hoboken); 2012 Jan; 64(1):132-7. PubMed ID: 21954226
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ.
    Ann Rheum Dis; 2016 Feb; 75(2):323-31. PubMed ID: 26338095
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, van Paassen P, Huizinga TWJ, Toes REM, van Kooten C, Rotmans JI, Rabelink TJ, Teng YKO.
    Trials; 2022 Nov 12; 23(1):939. PubMed ID: 36371234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.